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Abstract
TMPRSS2-ERG gene fusions occur in 50% of prostate cancers and result in the overexpression of a chimeric fusion
transcript that encodes a truncated ERG product. Previous attempts to detect truncated ERG products have been
hindered by a lack of specific antibodies. Here, we characterize a rabbit anti-ERG monoclonal antibody (clone EPR
3864; Epitomics, Burlingame, CA) using immunoblot analysis on prostate cancer cell lines, synthetic TMPRSS2-ERG
constructs, chromatin immunoprecipitation, and immunofluorescence. We correlated ERG protein expression with
the presence of ERG gene rearrangements in prostate cancer tissues using a combined immunohistochemistry (IHC)
and fluorescence in situ hybridization (FISH) analysis. We independently evaluated two patient cohorts and observed
Abbreviations: ERG, v-ets erythroblastosis virus E26 oncogene homolog (avian); TMA, tissue microarray; FISH, fluorescence in situ hybridization; ChIP, chromatin
immunoprecipitation
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ERG expression confined to prostate cancer cells and high-grade prostatic intraepithelial neoplasia associated with
ERG-positive cancer, as well as vessels and lymphocytes (where ERG has a known biologic role). Image analysis
of 131 cases demonstrated nearly 100% sensitivity for detecting ERG rearrangement prostate cancer, with only
2 (1.5%) of 131 cases demonstrating strong ERG protein expression without any known ERG gene fusion. The com-
bined pathology evaluation of 207 patient tumors for ERG protein expression had 95.7% sensitivity and 96.5% spec-
ificity for determining ERG rearrangement prostate cancer. In conclusion, this study qualifies a specific anti-ERG
antibody and demonstrates exquisite association between ERG gene rearrangement and truncated ERG protein
product expression. Given the ease of performing IHC versus FISH, ERG protein expression may be useful for
molecularly subtyping prostate cancer based on ERG rearrangement status and suggests clinical utility in prostate
needle biopsy evaluation.
Neoplasia (2010) 12, 590–598
Introduction
Vanaja et al. [1] first reported the overexpression of the oncogene ERG
(v-ets erythroblastosis virus E26 oncogene homolog [avian], chromo-
some 21q22.3) at the transcript level in 50% of clinically localized and
metastatic prostate cancer samples. Shortly after, Tomlins et al. [2]
demonstrated that the basis for this overexpression was due to a recur-
rent gene rearrangement involving the 5′ untranslated region of the
androgen-regulated TMPRSS2 gene with ETS family members, either
ERG or ETV1 (ets variant 1, chromosome 7p21.3). Numerous inde-
pendent studies confirmed the existence of ETS gene rearrangements
in prostate cancer, with TMPRSS2-ERG gene fusion being the most
common variant, seen in approximately 50% of all prostate-specific
antigen screened prostate cancers detected in the United States [3–5].
Subsequent works have demonstrated that ERG can be rearranged
and fused with SLC45A3 [6,7] or NDRG1 [7,8], accounting for ap-
proximately 5% of the ERG-overexpressing prostate cancers. The gene
fusion event occurs early in prostate cancer development, with ap-
proximately 15% of the precursor lesion, high-grade prostatic intra-
epithelial neoplasia (HG PIN), demonstrating ERG rearrangement
[9–11], however, only in immediate association with similarly ERG-
rearranged cancer. Gene fusions are not observed in benign prostate
epithelial glands, atrophy, or stroma as demonstrated by Perner et al.
[11] and additional studies using fluorescence in situ hybridization
(FISH) to determine ERG rearrangement status [4,5]. TMPRSS2-
ERG gene fusions result in a truncated ERG protein product, which
has been difficult to characterize given a lack of specific anti-ERG anti-
bodies for in vitro and in situ applications. Here, we qualify a novel
rabbit anti-ERG monoclonal antibody (clone EPR 3864; Epitomics,
Burlingame, CA) and demonstrate exquisite concordance between
ERG protein expression and the presence of ERG gene rearrangements
in prostate cancer using a combined IHC and FISH analysis. Given the
ease of performing IHC compared with FISH, our results demonstrat-
ing uniform ERG protein expression in most tumor cells with ERG
gene fusions, but not adjacent benign prostate tissue or stroma, suggest
diagnostic utility.
Materials and Methods
Cohort Description and Tissue Microarray Construction
The clinical cohorts studied consisted of 131 men from Weill
Cornell Medical College (WCMC) and 79 men from the University
of Michigan (UM) who underwent radical prostatectomy for clini-
cally localized prostate cancer as a monotherapy. The clinical demo-
graphics for the both cohorts are presented in Table 1. Four tissue
microarrays (TMAs; three from WCMC and one from UM) were
used for the study, representing tumors and benign prostate tissue
samples. The TMAs were constructed from formalin-fixed paraffin-
embedded tissue blocks from radical prostatectomy specimens. Re-
view of pathological findings and selection of tissue samples for the
TMAs were performed by the study pathologists. The TMAs from
WCMC were composed of three representative TMA cores of the
primary tumor consisting of the tumor with the highest Gleason
pattern (three 0.6-mm cores) from 131 patients. Secondary tumors
were sampled when present. In addition, normal prostatic tissue was
selected in a subset of cases. The TMA from UM consisted of one
TMA core sampled from 79 patients. Cases were selected in part
based on previous assessment of ETS rearrangement status by FISH
as described [6,12]. All patients provided written informed consent,
and this study was approved by the institutional review boards at
WCMC and at the UM Medical School, respectively.
Table 1. Clinical and Pathological Demographics of Cohorts from WCMC and UM.
WCMC Patients
(n = 131)
UM Patients
(n = 79)
Age, median (range), years 61 (42-75) 58 (45-77)
Clinical stage T1c 115 (88%) 62 (78%)
T2 16 (12%) 17 (22%)
Preoperative PSA, median (range), ng/ml 6.1 (1.1-24.2) 6.4 (0.5-18.4)
Prostatectomy Gleason score 6 19 (14%) 6 (8%)
7 98 (75%) 70 (90%)
8-9 14 (11%) 2 (3%)
Tumor stage pT2a-c 92 (70%) 64 (81%)
pT3a 30 (23%) 13 (16%)
pT3b 6 (5%) 1 (1%)
pT4 3 (2%) 1 (1%)
Surgical margin status No 111 (85%) 61 (77%)
Yes 20 (15%) 18 (23%)
PSA biochemical recurrence No 121 (92%) 70 (89%)
Yes 10 (8%) 9 (11%)
Vascular invasion status No 122 (93%) N/A
Yes 9 (7%)
Lymph node status Negative 130 (99%) 78 (99%)
Positive 1 (1%) 1 (1%)
N/A indicates not available.
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Assessment of Gene Rearrangement Status Using Two-color
Interphase FISH
Four-micrometer-thick TMA sections were used for interphase
FISH analysis. Rearrangement status for individual cohorts was deter-
mined independently at WCMC and UM by the study pathologists
using a dual-color break-apart interphase FISH assay as described pre-
viously [2,13]. Briefly, two differentially labeled probes were designed
to span the telomeric and centromeric neighboring regions of each
locus. ERG status was evaluated for all 207 cases on four TMAs. We
have previously evaluated 88 patients from two TMAs from the
WCMC cohort for three other ETS genes, namely, ETV1, ETV4 and
ETV5, and four known five prime fusion partners, namely, TMPRSS2,
SLC45A3, NDRG1, and Herv-K22q11.23 (Svensson and Rubin, un-
published observations). The following centromeric/telomeric BAC
clones were used to assess for rearrangement status in the WCMC
cohort: ERG (RP11-24A11 and RP11-372O17), ETV1 (RP11-661L15
and RP11-79G16), ETV5 (RP11-480B15 and RP11-822O23), ETV4
(CTP-3215I16 and RP11-147C10), TMPRSS2 (RP11-35C4 and
RP11-120C17), SLC45A3 (RP11-249H15 and RP11-131E5),NDRG1
(RP11-185E14 and RP11-1145H17), and Herv-K22q11.23 (RP11-
61N10 and RP11-71G19). RP11-95I21 (5′ to ERG ) and RP11-
476D17 (3′ to ERG ) were used in the UM cohort.
For all FISH experiments using break-apart probes, a nucleus with-
out a rearrangement demonstrates two pairs of juxtaposed red and
green signals (mostly forming two yellow signals). A nucleus with
rearrangement through insertion shows the split of one red-green
(yellow) signal pair, resulting in a single red and green signal for the
rearranged allele, and a still combined (yellow) signal for the nonre-
arranged allele in each nucleus. Finally, a nucleus with a rearrangement
through deletion shows one juxtaposed red-green signal pair (yellow)
for the nonrearranged allele and a single red signal for the allele in-
volved in the rearrangement. For each case, at least 100 cancer nuclei
were assessed. Benign epithelial and stromal cells served as internal
controls for most TMA cores evaluated.
Evaluation of ERG Protein Expression by IHC
Immunohistochemical (IHC) analyses on paraffin-embedded formalin-
fixed tumor tissue sections were carried out using the automated Dis-
coveryXT staining platform from Ventana Medical Systems. The pri-
mary rabbit monoclonal antibody was obtained from Epitomics (San
Diego, CA). Antigen recovery was conducted using heat retrieval and
CC1 standard, a high pH Tris/borate/EDTA buffer (VMSI, catalog
no. 950-124). Slides were incubated with 1:100 of the ERG primary
antibody for 1 hour at room temperature. Primary antibody was de-
tected using the ChromoMap DAB detection kit (VMSI, catalog no.
760-159) andUltraMap anti-RbHRP (VMSI, catalog no. 760-4315).
The anti-Rb HRP secondary antibody was applied for 16 minutes at
room temperature. Slides were counterstained with Hematoxylin II
(VMSI, catalog no. 790-2208) for 8 minutes followed by Bluing Re-
agent (VMSI, catalog no. 760-2037) for 4 minutes at 37°C. Subjective
evaluation of ERG protein expression in both the WCMC and UM
cohorts was determined for each tumor core using a four-tier grading
system: negative (0), weakly positive (1+), moderately positive (2+),
and strongly positive (3+). In addition, benign prostate glands, benign
prostatic hyperplasia, and HG PIN (isolated and associated with adeno-
carcinoma) were evaluated. Altogether, 207 cases from WCMC and
UM were assessable both for ERG rearrangement by FISH and for
ERG protein expression by the study pathologists.
A subset of cases (WCMC cohort) were also scanned using the Ariol
Platform (Genetix Corp, San Jose, CA) for objective measurements
of ERG protein expression. This microscope system scans the entire
TMA slide at 20× magnification. The image analysis component
was run with the Multistain assay on the Ariol 3.2.125 software ver-
sion. The color and shape characteristics (“classifiers”) were set by the
investigator to properly identify cells with positive staining. The soft-
ware applies the color classifiers to identify regions of positive nuclear
staining, excluding objects that are either too light or too dark. The
shape classifiers are applied to the remaining objects to further screen
out objects that do not resemble cells of interest. After determining
that endothelial cells and lymphocytes consistently express ERG pro-
tein, endothelial cell and lymphocyte masking was applied to each slide
to avoid measuring ERG expression from the endothelial compart-
ment. A total of 131 cases were assessed for ERG protein expression
using the Ariol Platform.
Cell Line Immunoblot Analyses
Lysates from benign (RWPE and PrEC) and cancerous (LNCaP,
VCaP, DU145) prostatic cell lines were transferred to polyvinylidene
fluoride membranes and probed with rabbit monoclonal anti-ERG
(clone EPR3864; Epitomics) at 1:1000 dilution. Membranes were
stripped and reprobed with mouse monoclonal anti–β-actin (clone
AC-74; Sigma, St Louis, MO) at 1:20,000 dilution for loading control.
Antibody Epitope Mapping
DNA expression vectors encoding ERG deletion constructs with
3′ 3×FLAG tags were purchased from GeneART (Regensburg, Ger-
many). HEK293 cells were transiently transfected with complementary
DNA expression vectors 48 hours before lysis. Immunoblot anal-
ysis was as above, except rabbit monoclonal anti-FLAG (no. F7425;
Sigma) at 1:1000 dilution was used for loading control.
Immunofluorescence
Formalin-fixed paraffin-embedded prostate tissue sections were
soaked in xylene for 1 hour to remove paraffin, and antigen retrieval
was performed using Target Retrieval Solution (Dako). Slides were
blocked in PBS-T containing 5% normal donkey serum for 1 hour.
Slides were incubated overnight at 4°C with rabbit monoclonal anti-
ERG (clone EPR3864, 1:200 dilution; Epitomics), washed, and incu-
bated with donkey antirabbit Alexa 488 (1:1000 dilution; Invitrogen,
Carlsbad, CA) for 1 hour. Slides were mounted using Vectashield
mounting medium containing 4′,6-diamidino-2-phenylindole-2HCl
(Vector Laboratories, Burlingame, CA) after washing with PBS-T
and PBS. Confocal images were taken with a Zeiss LSM510 META
(Carl Zeiss, San Francisco, CA) imaging system.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out on sta-
ble RWPE-ERG or RWPE-GUS (control) cells [14] as previously
described [15] using 5 μg of rabbit monoclonal anti-ERG (clone
EPR3864; Epitomics) or rabbit immunoglobulin G (no. sc-2027;
Santa Cruz Biotechnology, Santa Cruz, CA). The final ChIP yield
was 10 to 30 ng for each antibody. Quantitative polymerase chain re-
action (PCR) after ChIP was performed for ERG target genes PLAU,
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MMP3, and the TMPRSS2 enhancer and for control gene KIAA0066
as described [15].
Statistical Analysis
The objective ERG protein expression level by Ariol system was
defined as the ratio of “ERG nuclear area” to “analyzed tissue area.”
Because ERG protein expressions were collected from three represen-
tative TMA cores and multiple focus for each patient, the average of
ratios from three cores for each focus was calculated. When multiple
foci were available from one patient, we prioritized the focus with ERG
rearrangement (FISH) or maximum protein expression for each pa-
tient. Once the focus was selected for each patient, the corresponding
subjective pathologist evaluation of ERG protein expression by IHC
was used. The distribution of objective ERG protein expression (con-
tinuous scale) stratified by the study pathologists (categorical) or by
ERG rearrangement status (categorical) was assessed by descriptive sta-
tistic and box plots (box showing the first, median, and third quartiles;
and whiskers showing the 10th and 90th percentiles). Wilcoxon rank-
sum test was used to evaluate the association between a continuous
variable and a categorical variable (two-group). The Bonferroni adjust-
ment was used for multiple tests between groups. To compare the pre-
dicted accuracy of ERG protein expression (both categorical and
Figure 1. Characterization of a monoclonal anti-ERG antibody for detecting TMPRSS2-ERG gene fusion expression products. (A) Immu-
noblot detection of endogenous TMPRSS2-ERG gene fusion product (predicted molecular weight, 49.0 kDa) using anti-ERG monoclonal
antibody. Cell lysates from benign (PrEC and RWPE) and cancerous (LNCaP, VCaP, and DU145) prostatic epithelial cell lines were immu-
noblotted for ERG expression using the rabbit monoclonal anti-ERG antibody. VCaP harbors a TMPRSS2-ERG gene fusion resulting in
marked overexpression of ERG, LNCaP harbors a rearrangement of the entire ETV1 locus, resulting in marked overexpression of ETV1,
and no ETS gene rearrangements have been identified in DU145. β-Actin was used as a loading control. (B) Schematic diagram showing
different ERG deletion constructs used to identify the anti-ERG epitope. Constructs detected by the antibody are shown in red. (C)Western
blot analysis of HEK293 cells transiently mock-transfected (showing endogenous ERG expression) or transfected with the constructs in
panel B, and blotted with anti-ERG or anti-FLAG as loading control. (D) ChIP–quantitative PCR assays from stable RWPE-ERG and RWPE-
GUS (control) cells, for ERG target genes PLAU,MMP3, and the TMPRSS2 enhancer, and the negative control gene KIAA0066. Means±SE
are shown. Experiments were run in triplicate. (E) Immunofluorescence with anti-ERG on a formalin-fixed paraffin-embedded prostate
tissue section with a TMPRSS2:ERG–positive tumor demonstrates strong nuclear staining in neoplastic cells. Endothelial cells in the
stromal compartment also demonstrate expression of ERG.
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continuous) to ERG rearrangement status (criterion standard), sen-
sitivity, specificity, and positive (PPV) and negative (NPV) predictive
values were calculated. In addition, receiver operating characteristic
(ROC) curve was plotted, and the area under the curve (AUC) was
assessed. κ Statistic was calculated to determine the agreement between
subjective ERG protein expression and automated image analysis ERG
protein expression. Associations for ERG expression status and clinical
and pathologic features were also explored by χ 2 or Fisher exact test
where applicable. Analyses were performed in SAS Version 9.2 (SAS
Institute, Inc., Cary, NC).
Results
Characterization of Anti-ERG Antibody for Assessing ERG
Gene Fusion Prostate Cancer
Because almost all reported TMPRSS2-ERG transcript isoforms en-
code for a truncated ERG protein rather than a chimeric protein, an
antibody-based detection strategy would need to target the 3′ end of
ERG. We previously evaluated multiple commercially available anti-
ERG antibodies but could not identify any that were both sensitive and
specific for ERG rearrangement prostate cancer through in vitro and
in situ experiments (S.A. Tomlins, R. Mehra, and A.M. Chinnaiyan,
unpublished observations). Here we sought to characterize and qualify
a novel rabbit monoclonal anti-ERG antibody. First, we assessed cell
lysates from benign (PrEC and RWPE) and cancerous (LNCaP, VCaP,
DU145) prostatic epithelial cell lines for ERG expression using immu-
noblot analysis with the rabbit monoclonal anti-ERG antibody. Im-
portantly, VCaP harbors a TMPRSS2-ERG gene fusion resulting in
marked overexpression of ERG, whereas LNCaP harbors a rearrange-
ment of the entire ETV1 locus, resulting in marked overexpression of
ETV1, and no ETS gene rearrangements have been identified in DU145.
As expected, the antibody showed marked overexpression of ERG in
VCaP cells, with minimal background signal in the other cell lines and
no cross-reactivity with ETV1 in LNCaP cells (Figure 1A).
Figure 2. ERG rearrangement by break-apart FISH is highly correlated with ERG protein expression by IHC. (A) ERG protein expression in
tumors with and without the TMPRSS2-ERG gene fusion. The endothelial cells of small vessels show positive endogenous ERG expres-
sion in the context of surrounding ERG-negative cancer glands (left 20×, right 40×). (B) The box plot demonstrates a highly significant
association between the automated image evaluation of ERG protein expression and the ERG gene rearrangement status for 128 cases
(P < .0001, Wilcoxon rank-sum test). Of 70 ERG rearrangement–negative cases, 2 demonstrate ERG protein expression. (C) Using a
threshold of 0.4 as the cut point for determining ERG status, we observed excellent ROC curve performance with an AUC of 0.98 using
ERG rearrangement by FISH as the criterion standard. (D) A summary of the performance of ERG protein expression to predict ERG
rearrangement status is presented for different thresholds.
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Next, we mapped the antibody binding site on ERG through im-
munoblot analysis on a series of expression vectors representing por-
tions of the most prevalent gene fusion protein (TMPRSS2 exon 1 to
ERG1 exon 2) by making large tilling deletions of the N-terminus
(ΔN-term, deletion of 47-115, 44.6 kDa), pointed domain (ΔPNT,
deletion of 115-197, 43.4 kDa), the middle (ΔMID, deletion of
197-310, 41.6 kDa), the ETS domain (ΔETS, deletion of 310-393,
43.7 kDa), or the C-terminus (ΔC-term, deletion of 393-479,
43.6 kDa) of ERG. Triple FLAG antigen sequences were fused to
the C-terminus of each construct, which were transiently transfected
into HEK293 cells. As shown in Figure 1C , the antibody recognized
all constructs except ΔC-term, consistent with the antibody epitope
being found in the C-terminal amino acids 393-479 of the ERG pro-
tein, which is retained in all known ERG gene fusion isoforms. This
immunogenic region is also highly specific to ERG relative to other
ETS transcription factors.
We also assessed whether the anti-ERG antibody could recognize
ERG in ChIP experiments using stable RWPE-ERG or RWPE-GUS
(control) cells [15]. The anti-ERG antibody was able to specifically
enrich known ERG target gene promoters including PLAU, MMP3,
and the TMPRSS2 enhancer in the RWPE-ERG cells (two-tailed t test,
P < .05 for all three targets), whereas no significant enrichment of these
targets was observed in RWPE-GUS cells. Similarly, the negative
control gene KIAA0066 was not specifically enriched by anti-ERG
in either cell line (Figure 1D). Finally, to characterize the antibody for
in situ experiments, we performed immunofluorescence on formalin-
fixed paraffin-embedded tissue sections with TMPRSS2:ERG–positive
prostate cancer (previously assessed by FISH), with almost all tumor
nuclei in cancerous foci showing strong nuclear protein expression
(Figure 1E ). In the same field, one can also appreciate endothelial cell
expression of ERG.
ERG Protein Expression Is Highly Concordant with
ERG Rearrangement
Previous studies demonstrated that ERG rearrangement prostate
cancer (ERG+) demonstrate high levels of ERG messenger RNA tran-
script [2,13], the current study extends this observation to ERG pro-
tein expression. Using TMAs from 131 cases, ERG protein expression
was evaluated by the study pathologists and by using the automated
Ariol imaging system. ERG protein expression was confined to neo-
plastic cells (Figure 2A), vessels, and lymphocytes (Figure W1). The
expression was strongly concentrated in the nuclei, but weak cytoplas-
mic expression could be appreciated in cases with strong nuclear ERG
protein expression. None of the benign prostate glands in any of the
samples reviewed demonstrated ERG protein expression. Using arbi-
trary expression units, the ERG protein expression was strongly asso-
ciated with ERG rearrangement status in 131 cases from the WCMC
cohort (median = 0.0 in ERG− vs 0.08 in ERG+, P < .0001) using the
Wilcoxon rank-sum test (Figure 2B).
We identified two cases demonstrating ERG protein expression
(Figure W2) without any detectable ERG rearrangement as deter-
mined by FISH and reverse transcription–PCR. Conversely, three
cases with ERG rearrangement by FISH had nearly no ERG protein
expression. The sensitivity and specificity for using ERG protein ex-
pression on a continuous scale to predict ERG rearrangement status
are presented in the ROC plot (Figure 2C ). The AUC was 0.98.
The PPV, sensitivity, NPV, and specificity based on variable ERG pro-
tein expression thresholds demonstrate that even low levels of expres-
sion are highly suggestive of ERG rearrangement (Figure 2D). By
applying increasing thresholds to the protein expression levels, increased
specificity and decreased sensitivity are observed.
We next explored the correlation between the subjective evaluation
by the study pathologists for ERG protein expression for 128 cases
from WCMC (three cases were excluded by the pathologists) and by
automated imaging. The correlation demonstrated nearly perfect agree-
ment [16] with a κ statistic of 0.84 (0.75–0.94) (Figure W3). Interest-
ingly, no ERG protein negative cases (n = 66) evaluated by the study
pathologists demonstrated ERG rearrangement by FISH. Two cases
with no known ERG rearrangement were scored as having moderate
ERG protein expression. Importantly, these results were independently
confirmed in a second cohort with 79 patients from the UM (Table 2).
The combined evaluations from both cohorts consisting of 207 patient
tumors that could be evaluated by the pathologists demonstrated a sen-
sitivity and specificity of 95.7% and 96.5%, respectively. Interestingly,
between the two cohorts, there were six cases harboring either ETV1
(n = 4 or 1.9%), ETV4 (n = 1 or 0.48%), or ETV5 (n = 1 or
0.48%) rearrangements (all ERG rearrangement–negative). None of
these cases demonstrated ERG protein expression (Figure W4), sup-
porting the in vitro specificity of the antibody described above.
In the WCMC cohort, 47% (60/128) demonstrated ERG rear-
rangement by FISH with the majority harboring the TMPRSS2-
ERG gene fusion (n = 57) and the remaining cases demonstrating
either the SLC45A3-ERG (n = 2) or the NDRG1-ERG (n = 1) gene
fusions. We did not appreciate any differences in protein expression
in these other types of ERG rearranged cancers, although the numbers
are too small to make any conclusive comments (Figure 3). The UM
cohort was selected based on previous assessment of ETS status, and
the prevalence 40% (32/79) of ERG rearranged cases is thus not rep-
resentative of our prostatectomy series.
ERG rearrangement heterogeneity has been well documented be-
tween discrete tumor nodules within the same prostate gland [17,18].
In this cohort, we had an example of two geographically discrete tumors
from the same patient, with one ERG rearrangement positive and the
other negative. As expected, ERG protein was strongly expressed in the
ERG-rearranged case, and no expression was observed in the fusion-
negative tumor (Figure W5). These findings are consistent with obser-
vations that multifocal localized prostate cancer is clonally distinct and
that ERG rearrangement (through FISH or protein expression) can be
used as a clonal marker.
Table 2. Pathological Evaluation of ERG Protein Expression Versus ERG Rearrangement Status
as Determined by FISH in Cohorts from the WCMC and the UM Cohorts.
ERG Status Patient Cohort
Pathologist
evaluation
Positive Negative Combined Sensitivity 95.7%
Positive 88 4 Specificity 96.5%
Negative 4 111 PPV 95.7%
NPV 96.5%
Fisher = 6.07e − 48
Pathologist
evaluation
Positive Negative WCMC Sensitivity 100.0%
Positive 60 2 Specificity 97.1%
Negative 0 66 PPV 96.8%
NPV 100.0%
Fisher = 1.01e − 34
Pathologist
evaluation
Positive Negative UM Sensitivity 87.5%
Positive 28 2 Specificity 95.7%
Negative 4 45 PPV 93.3%
NPV 91.8%
Fisher = 7.05e − 15
ERG FISH: negative versus positive (insertion + deletion); IHC: negative versus (weak + moderate +
strong). Note that for the WCMC cohort, 128 cases were evaluated.
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ERG Protein Expression Is Present in High-grade PIN
Associated with ERG-Expressing Carcinoma
We also had several areas with HG PIN from cases harboring ERG
rearrangement. We observed similar ERG expression status in HG
PIN and associated adjacent prostate cancer (Figure 4), consistent with
previous FISH-based studies [17–19]. Interestingly, one can appre-
ciate a distinct demarcation where HG PIN begins morphologically
(Figure 4A, arrowhead ), and in this ERG rearrangement–positive can-
cer, the ERG protein expression clearly identifies the initiation of
HG PIN (Figure 4B, arrowhead ).
Expression in Vessels/Endothelial Cells and Lymphocytes
As described above, the endothelial cells of small vessels in benign
and cancerous prostate tissue demonstrated moderate to strong ERG
protein expression, regardless of tumor ERG rearrangement status.
In addition, lymphocytes in both benign and cancerous tissue also
demonstrated ERG protein expression (Figure W1). However, ERG
rearrangements were never detected by FISH in endothelial cells
or lymphocytes.
Lack of Correlation with Clinical or Pathology Parameters
In the WCMC cohort (n = 128) and UM (n = 79) cohorts, we did
not observe any associations between ERG rearrangement status and
clinical or pathologic parameters (data not shown) and did not have
sufficient follow-up to explore for clinical outcome.
Discussion
The current study demonstrates that recurrent ERG gene fusions lead
to the over expression of a truncated ERG protein.When ERG protein
is expressed in tumor cells, most of the tumor nuclei are positive con-
sistent with earlier observations by FISH [2,11,13]. A range of ERG
expression levels was observed in these clinically localized prostate can-
cer cases; however, this was in contrast to benign glands, which never
showed staining, consistent with previous FISH results. We did not
appreciate ERG protein expression differences based on the mecha-
nism of ERG rearrangement (i.e., through deletion or insertion; data
not shown). We also did not observe differences in ERG protein
expression based on the involved 5′ partners of ERG, including
TMPRSS2, SLC45A3, and NDRG1. Likewise, we saw no cross-
reactivity with cases harboring ETV1, ETV4, or ETV5 rearrangements.
Although we observed highly consistent results for ERG rearrangements
by FISH and for ERG expression by IHC, we did not observe perfect
concordance. In addition to technical factors, such discordant cases may
be due to 1) ERG rearrangement but decreased transcript/protein
expression (e.g., due to decreased androgen signaling); 2) insertion of
the entire ERG locus into a genomically active region, which does not
result in an ERG rearrangement detectable by split-signal FISH but re-
sults in transcript/protein overexpression (similar to the mechanism for
ETV1 rearrangement in LNCaP [5]; and 3) activation of ERG over-
expression by a non–rearrangement-based mechanism. The combined
FISH/IHC strategy used herein will allow for identification of such
cases in future studies.
Figure 3. ERG-rearranged cases express high levels of truncated ERG protein regardless of 5′ fusion partner. Representative examples of
prostate cancers harboring ERG rearrangements with different 5′ partners but showing similar ERG protein expression by IHC.
Figure 4. ERG protein expression in high-grade prostatic intraepithelial neoplasia (HG PIN) adjacent to ERG-expressing cancer. (A) H&E
stain demonstrates small prostatic cancerous glands on the left and a larger atypical gland on the right with a subset of epithelial cells
with neoplastic features consistent with HG PIN. (B) ERG protein expression by IHC demonstrates strong expression in both cancer and
HG PIN. The arrowheads indicate a discrete demarcation between HG PIN and histologically benign luminal epithelial cells (40×).
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In the current study, we observed ERG protein expression in vessels
surrounding prostate cancer, consistent with staining of endogenous
wild-type ERG, which is known to be expressed during angiogenesis
(reviewed by Sato [20]). Vlaeminck-Guillem et al. [21] first described
ERG gene expression duringmurine embryogenesis inmesodermal tis-
sues, including the endothelial, precartilaginous, and urogeni-
tal areas. Importantly, ERG rearrangements by FISH were never
observed in endothelial cells or lymphocytes, consistent with the
observed staining representing endogenous wild-type ERG expres-
sion. Supporting this, expression in vessels and lymphocytes was
not related to ERG rearrangement status of the tumor and was not
cancer-specific, as ERG expressions in both vessels and lympho-
cytes adjacent to benign prostate tissue and stroma were observed
(Figure W1). This is consistent with original observations made by
Gavrilov et al. [22] describing the protein expression of ERG in
small-caliber vessels adjacent to prostate cancer using IHC. The ERG
protein expression of vessels and lymphocytes can be conveniently
used as an internal staining control, regardless of ERG rearrangement
status in cancer.
Because prostate needle biopsies can be readily evaluated for ERG
protein expression (Figure 5), ERG staining may have immediate clin-
ical utility in cases with atypical small acinar proliferation or HG PIN.
Given the specificity of ERG staining for cancer observed herein, ERG
staining in an atypical focus would be highly suggestive of cancer and
evidence to support expedited rebiopsy. In addition to highly specific
staining for cancer, we also observed a distinct demarcation between
ERG-expressing HG PIN and adjacent benign glands (Figure 4). Im-
portantly, HG PIN with ERG staining was always located adjacent to
cancer with similar levels of ERG protein expression, consistent with
previous FISH results demonstrating that ERG-rearranged HG PIN is
nearly always found in close association with ERG-rearranged cancer
[9–11]. Thus, ERG expression in isolated HG PIN would be highly
suspicious for unsampled adjacent cancer or for the rapid progression
to invasive disease. The utility of this finding will need to be evaluated
in future clinical studies.
An antibody-based detection strategy for ERG rearrangement status
may also have utility in the setting of castrate-resistant metastatic pros-
tate cancer. We anticipate that ERG expression should be maintained
in castrate-resistant cancers with ERG rearrangements because most of
these tumors have selected for mechanisms to restore androgen signal-
ing [4] and continue to express high levels of the gene fusion transcript
[2,23]. Intriguingly, phase 1/2 results in men with castrate-resistant
cancers treated with the novel antiandrogen abiraterone acetate demon-
strated higher maximal prostate-specific antigen response in men with
ERG rearrangement–positive versus –negative tumors, suggesting the
potential utility of antibody- and/or FISH-based assessments of ERG
rearrangement status for patient stratification. Importantly, FISH only
demonstrates the presence of an ERG rearrangement, whereas con-
tinued ERG protein expression indicates both ERG rearrangement
and continued androgen signaling (because androgen signaling–
independent cancers with ERG rearrangements express low or no de-
tectable TMPRSS2-ERG transcript) [24,25]. Antibody-based detection
may also facilitate screening for ERG rearrangements in other clinical
cohorts for molecular stratification, with possible confirmation by
FISH (because IHC does not show perfect concordance with FISH
and cannot determine fusion mechanism).
This current study is not the first to explore ERG expression in the
prostate. Gavrilov et al. [22] described the protein expression of several
ETS family members in prostate tissue samples using IHC. They
reported nuclear expression of Elf-1 and Fli-1 in 16 and 20 of 25
high-grade PCA, respectively. Interestingly, ERG expression was only
observed in 44% (11/25) of PCA samples tested, of which 7 had a
Gleason score of 7 or higher. Vanaja et al. [1] reported ERG overexpres-
sion by quantitative PCR in 50% of both hormone-naive and meta-
static prostate cancer samples. More recently, Petrovics et al. [26]
identified ERG as the most frequently overexpressed oncogene in
the transcriptome by using a combination of expression array analysis
and quantitative real-time reverse transcription–PCR on 114 PCA
samples isolated with laser capture microdissection.
In summary, we present the characterization of a specific rabbit
monoclonal anti-ERG antibody that shows very high concordance
with FISH, the current criterion standard for determining ERG rear-
rangement status in prostate cancer. In this study, we observed ERG
staining exclusively in prostate cancer and HG PIN, consistent with
FISH results, suggesting immediate potential clinical utility. In addi-
tion, this antibody will likely facilitate functional studies of ERG gene
fusions and molecular subtyping of prostate cancer.
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Figure W1. Endothelial cells and lymphocytes express endogenous ERG protein by IHC but not ERG rearrangements. The endothelial
cells of small vessels cut in cross section (A) and longitudinally (B) exhibit ERG protein expression. (C and D) Lymphocytes surrounding
benign glands also exhibit positive ERG staining. Representative FISH images of an endothelial cell (C) and a lymphocyte (D) showing
lack of ERG rearrangement (IHC 40×, FISH 60×).
Figure W2. ERG expression in rare cases without a detectable ERG rearrangement. Examples of two discrepant cases (A and B) with
ERG protein expression without ERG rearrangement by FISH.
Figure W3. Significant association between interpretation of ERG
protein expression by manual and automated image analyses.
Cases from the WCMC TMA were identified as ERG rearranged
(ERG+) or wild type (ERG−) by FISH, and ERG protein was as-
sessed manually by study pathologists as negative, weak, moder-
ate, or strong in neoplastic cells. Automated image analysis was
also performed for ERGexpression, and results are plotted stratified
onmanual staining intensity. No significant differencewas seen be-
tween weak andmoderate expressions after Bonferroni correction.
Subjective evaluation correctly classified all ERG-negative cases.
Boxes indicate the first, median, and third quartiles, and whiskers
indicate the 10th and 90th percentiles.
Figure W4. Anti-ERG antibody does not cross-react with other ETS rearrangements in prostate cancer. Representative examples of
other ETS rearrangement prostate cancers without ERG protein expression. The first case harbors an ETV1 rearrangement (unknown
5′ partner) and the second case harbors an SLC45A3-ETV5 gene fusion. In the study, we identified four cases with ETV1, one case with
ETV5, and one case with ETV4 rearrangements, all of which lacked ERG expression.
Figure W5. Molecular heterogeneity of multifocal localized prostate cancer demonstrated by ERG protein expression. (A) Two sets of
three TMA cores sampled from two discrete tumors from the same patient show distinct patterns of ERG protein expression. The three
cores on the top exhibit intense ERG protein expression (B), and the three on the bottom are negative for ERG protein expression (D)
with the corresponding FISH assays demonstrating ERG rearrangement through insertion (C) and the absence of ERG rearrangement
(E), respectively. IHC images were taken at ×20 objective magnification (A) and at ×40 magnification (B, D). FISH images (C, E) were
taken at ×60 magnification.
